Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds

Journal of Medicinal Chemistry

Volumn 39, Issue 18, 1996, Pages 3547-3555

  Ogawa, Hidenori ^a   Yamashita, Hiroshi ^a   Kondo, Kazumi ^a   Yamamura, Yoshitaka ^a   Miyamoto, Hisashi ^a   Kan, Keizo ^a   Kitano, Kazuyoshi ^a   Tanaka, Michinori ^a   Nakaya, Kenji ^a   Nakamura, Shigeki ^a   Mori, Toyoki ^a   Tominaga, Michiaki ^a   Yabuuchi, Youichi ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; BENZAZEPINE DERIVATIVE; MOZAVAPTAN; RECEPTOR BLOCKING AGENT; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MICTURITION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR BLOCKING;

ADMINISTRATION, ORAL; ANIMALS; BENZAZEPINES; RATS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9544238082     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960133o     Document Type: Article

References (30)

1. Manning, M.; Sawyer, W. H. Design, Synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 1993, 13, 195-214.
2. Kinter, L. B.; Huffman, W. F.; Stassen, F. L. Antagonists of the antidiuretic activity of vasopressin. Am. J. Phisiol. 1988, 254, F165-F177.
3. László, F. A.; László, F., Jr.; De Wied, D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 1991, 43, 73-108.
4. Manning, M.; Sawyer, W. H. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 1989, 114, 617-632.
5. Manning, M.; Chan, W. Y.; Sawyer, W. H. Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions. Regul. Pept. 1993, 45, 279-283.
6. Mah, S. C.; Hofbauer, K. G. Evaluation of the pharmacologic properties of a vasopressin antagonists in brattleboro rats. J. Pharmacol. Exp. Ther. 1988, 245, 1028-1032.
7. Huffman, W. F.; Albrightson-Winslow, C.; Brickson, B.; Bryan, H. G.; Caldwell, N.; Dytko, G.; Eggleston, D. S.; Kinter, L. B.; Moore, M. L.; Newlander, K. A.; Schmidt, D. B.; Silvestri, J. S.; Stassen, F. L.; Yim, N. C. F. A minor modification of residue 1 in potent vasopressin antagonists drastically reduces agonist activity. J. Med. Chem. 1989, 32, 880-884.
8. 1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinone. J. Med. Chem. 1993, 36, 2011-2017.
9. 1a, receptors. J. Clin. Invest. 1993, 92, 224-231.
10. Proctor, G. R. Azabenzocycloheptenones. Part III. 2,3,4,5-Tetrahydro-5-oxo-1-toluene-p-sulphonylbenz[b]azepine. J. Chem. Soc. 1961, 3989-3994.
11. For compound 7, see: Coudert, G.; Guillaumet, G.; Loubinoux, B. A new synthesis of 3,4-dihydro-2H-1,4-benzoxazines using solid-liquid phase transfer catalysis. Synthesis 1979, 541-543.
12. For compound 8, see: Watjen, F.; Hansen, H. C. Eur. Patent 283162, 1988.
13. For compound 9, see: Sasatani, S.; Miyazaki, T.; Maruoka, K.; Yamamoto, H. Diisobutylaluminum hydride, a novel reagent for the reduction of oximes. Tetrahedron Lett. 1983, 24, 4711-4712.
14. For compound 10, see: Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A. Condensed heterocycles. Beckmann rearrangement of xanthone and thioxanthone oximes as a route to dibenz[b,f][1,4]-oxazepines and thiazepines. Indian J. Chem. 1974, 12, 247-251.
15. For compound 11, see: Testa, E.; Fontanella, L. Substances active on central nervous system. XLIV. 3,5-Dihydro-4,1-benzoxazepin-2(1H)-ones and 1,2,3,5-tetrahydro-4,1-benzoxazepines. Farmaco (Pavia), Ed. Sci. 1965, 20, 323-335; Chem. Abstr. 1965, 63, 18088c.
16. For compound 11, see: Testa, E.; Fontanella, L. Substances active on central nervous system. XLIV. 3,5-Dihydro-4,1-benzoxazepin-2(1H)-ones and 1,2,3,5-tetrahydro-4,1-benzoxazepines. Farmaco (Pavia), Ed. Sci. 1965, 20, 323-335; Chem. Abstr. 1965, 63, 18088c.
17. For compound 12; see: Misiti, D.; Gatta, F.; Landi-Vittory, R. 1,2,3,5-Tetrahydro-4H-1,5-benzodiazepin-4-ones and 1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-ones from the reaction of hydrazoic acid on 1,2,3,4-tetrahydroquinoline-4one-5. J. Heterocycl. Chem. 1971, 8, 231-236.
18. For compound 13, see: Lehmann, J.; Kraft, G. Amphiphilic compounds, I. Synthesis of 1-aryl-, 1-aroyl- and 1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepines. Arch. Pharm. 1984, 317, 595-606.
19. For compound 14, see: Jedrichovsky, J.; Rybar, A.; Frimm, R. 1,2,3,4,5,6-Hexahydro-1-benzazocine, Czech. Patent 210993, 1984; Chem. Abstr. 1984, 101, 130603.
20. For compound 15, see: Bell, W. H.; Hannah, E. D.; Proctor, G. R. Azabenzocycloheptenones. Part V. 2,3,4,5-Tetrahydro-5-oxobenz[b]azepines. J. Chem. Soc. 1964, 4926-4930.
21. Nakahara, T.; Terada, S.; Pincus, J.; Flouret, G.; Hechter, O. Neurohypophyseal hormone-responsive renal adenylate hormone-sensitive adenylate cyclase in bovine renal medullary membranes prepared using a double phase polymer system. J. Biol. Chem. 1978, 253, 3211-3218.
22. Nakamura, T.; Tomomura, A.; Noda, C.; Shimoji, M.; Ichihara, A. Acquisition of a β-adrenergic response by adult rat hepato-cytes during primary culture. J. Biol. Chem. 1983, 258, 9283-9289.
23. Yamamura, Y.; Ogawa, H.; Yamashita, H.; Chihara, T.; Miyamoto, H.; Nakamura, S.; Onogawa, T.; Yamashita, T.; Hosokawa, T.; Mori, T.; Tominaga, M.; Yabuuchi, Y. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 1992, 105, 787-791.
24. 1 receptor antagonist. Science 1991, 252, 572-574.
25. 28 of compounds 31b and 31s. Compound 31b adopts an extended trans conformation compared to the N-methyl amide 31s. These findings suggest that the conformational change by the N-methylation of benzanilide may be a predominant factor in lowering the binding affinity to the receptors.
26. Ohnishi, A.; Orita, Y.; Okahara, R.; Fujihara, H.; Inoue, T.; Yamamura, Y.; Yabuuchi, Y.; Tanaka, T. Potent aquaretic agent. J. Clin. Invest. 1993, 92, 2653-2659.
27. 2 antagonist in men. J. Pharmacol. Exp. Ther. 1995, 272, 546-551.
28. Toriumi, Y.; Kasuya, A.; Itai, A. Crystallographic studies on retinoidal-active and -inactive aromatic anilides. J. Org. Chem. 1990, 55, 259-263.
29. Energy minimization calculations were carried out with use of CHARMM, and molecular modeling was performed with the QUANTA software (Molecular Simulations Inc.).
30. Nagarajan, K.; Madhavan Pillai, P.; Bhute, R. S. Synthesis of pyrido[3,2,1-de]phenanthridine derivatives. Indian J. Chem. 1969, 7, 848-858.